Available EU DMF/CEP
EU DMF
CEP
API Status
Commercial
Pipeline
Therapeutic Category
Alimentary tract & metabolism
Anti-infectives for systemic use
Antipyretic, analgesic and anti-inflammatory
Antineoplastic & immunomodulating agents
Blood & blood forming organs
Cardiovascular system
Genito-urinary system & sex hormones
Injectable forms
Musculo-skeletal system
Nervous system
Opthalmological preparations
Respiratory system
Available US DMF
US DMF
Available Japanese/Chinese DMF
Japanese DMF
Chinese DMF
Korean DMF

Linaclotide

CAS No.

851199-59-2

Innovator/marketer

Constella

Polymorphic form

Amorphous

Therapeutic Area

Alimentary tract & metabolism

Status

Pipeline

US DMF readiness

Dmf preparation upon request

Drug description:

Linaclotide is an anti-constipation agent.
Linaclotide is indicated for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation.
It is formulated as capsule and tablet for oral route of administration.


Mechanism of action:

Linaclotide is an agonist of guanylate cyclase type-C (GC-C), a receptor found on epithelial cells lining the intestine. Linaclotide promotes activation of the CFTR chloride channel. Activation of intestinal GC-C induces secretion of fluid, sodium and bicarbonate in the intestinal lumen. The activation of GC-C leads to increases in cyclic guanosine monophosphate (cGMP), anion secretion, fluid secretion, and intestinal transit. In addition, both linaclotide and cGMP demonstrated anti-nociceptive effects in several preclinical models of visceral pain.

DISCLAIMER
The above product is presented solely for informational purposes and does not constitute an offer in any sense. Products under patent (SPC) protection in Poland and/or other countries are not offered until expiration of the corresponding IP right.

OK